Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model

Jianzheng Wang, Jinxi Huang, Hui Wang, Wei Yang, Qiwen Bai, Zhentao Yao, Qingli Li, Huifang Lv, Beibei Chen, Caiyun Nie, Weifeng Xu, Shuiping Tu, Hongle Li, Xiaobing ChenJournal of Oncology 2022 · DOI

TL;DR

This paper introduces the MiniPDX model as a rapid and effective method for predicting drug sensitivity in advanced gastric cancer patients. By establishing personalized mini-xenograft models from patient tumors, clinicians can quickly identify effective treatment regimens, potentially improving patient outcomes and avoiding ineffective therapies.

What Problem Does This Paper Address?

Gastric cancer is a leading cause of cancer-related death worldwide, often diagnosed at an advanced stage with a poor prognosis. While first-line treatments have established options, choosing personalized and effective therapies for patients who develop drug resistance after initial treatment remains a significant challenge. Traditional methods for predicting drug efficacy, like patient-derived xenografts (PDX), are time-consuming, taking up to six months, which is often too long for patients with rapidly progressing disease. This delay hinders timely adjustments to treatment, impacting patient outcomes. The paper addresses the urgent need for a faster, more accurate method to guide personalized treatment decisions for advanced gastric cancer patients, especially those with drug resistance.

Methods

The study utilizes the OncoVee® MiniPDX system to establish personalized drug sensitivity models. The core methodology involves:

  • Tissue Biopsy: Obtaining tumor tissue samples from advanced gastric cancer patients via endoscopy.
  • MiniPDX Model Establishment: Digesting the tumor tissue and implanting the resulting cell suspension into immunocompromised mice within specialized capsules. This process is significantly faster than traditional PDX models.
  • Drug Sensitivity Testing: Treating the MiniPDX models with various chemotherapy and targeted drug regimens. The efficacy of these treatments is assessed by measuring tumor cell proliferation using a luminescence assay. A relative proliferation rate (RPR) below 55% is considered a positive drug response.
  • Side Effect Prediction: Evaluating potential severe side effects by monitoring the weight loss of the mice. A weight loss exceeding 15% over a 7-day treatment period suggests a regimen might cause significant toxicity.
  • Personalized Treatment Guidance: Based on the MiniPDX drug sensitivity test results and considering potential side effects, a personalized therapeutic regimen is formulated for the patient.

Datasets

The study involved four patients with advanced gastric cancer who had progressed after previous treatments. Baseline information collected for each patient included age, gender, medical history, tumor staging, pathological types, Lauren's classification, HER2 status, imaging examination results, and metastatic sites. The MiniPDX models were established from biopsy tissues of these four patients' primary gastric cancer lesions.

Key Insights and Ideas

  • Speed is Crucial: The MiniPDX model's ability to deliver drug sensitivity results within 7-10 days is a critical advantage over traditional PDX models, making it suitable for patients with advanced, rapidly progressing cancers.
  • Personalized Efficacy: The study demonstrates that MiniPDX can identify potentially effective drugs for individual patients, leading to personalized treatment plans.
  • Predicting Toxicity: The model's capacity to predict potential severe side effects by monitoring mouse weight loss adds another layer of personalization, helping to avoid toxic regimens.
  • Clinical Relevance: The paper suggests that MiniPDX can serve as a valuable supplement to existing treatment options, guiding clinicians in selecting the most appropriate drugs and improving patient clinical benefits.

Key Results

  • The study successfully established MiniPDX models for four patients with advanced gastric cancer.
  • Based on MiniPDX predictions, personalized treatment regimens were administered to these patients.
  • Two out of the four patients achieved a partial response (PR) to their guided treatments.
  • The remaining two patients showed disease progression (PD).
  • No severe side effects were observed in the patients following the MiniPDX-guided treatment plans, aligning with the side effect predictions from the mouse models.

Limitations and Future Work

The authors acknowledge several limitations:

  • Tissue Biopsy Location: Difficulty in obtaining biopsy samples from metastases, leading to models derived only from primary tumors, which might not fully represent the heterogeneity of the disease.
  • Immunotherapy Evaluation: The MiniPDX mouse models are immunocompromised, limiting the direct evaluation of immunotherapy or combined chemo-immunotherapy regimens.
  • Drug Administration Differences: The duration and cycle of drug administration in mice differ from human protocols, potentially impacting the direct translation of results.
  • Microenvironment Disruption: The process of isolating tumor tissue into single-cell suspension might affect the tumor microenvironment.
  • Small Sample Size: The study was limited to four patients, and a lack of a control group receiving conventional chemotherapy.
  • Limited Follow-up: The study did not include long-term follow-up data such as overall survival (OS) and progression-free survival (PFS).

Future work should focus on addressing these limitations, including conducting larger, randomized controlled clinical trials to further validate the MiniPDX technology for advanced gastric cancer treatment. Developing methods to incorporate immunotherapy into MiniPDX models and refining drug administration protocols to better mimic human treatments are also important areas for future research.

Summary updated

Abstract

Establishing a personalized drug screening system for patients with drug-resistant gastric cancer can guide the selection of clinical drugs, improve the clinical benefit of patients, and avoid ineffective treatments. It can be an effective supplement for treatment options.
BibTeX
@article{wang2022personalized,
  author = {Jianzheng Wang and Jinxi Huang and Hui Wang and Wei Yang and Qiwen Bai and Zhentao Yao and Qingli Li and Huifang Lv and Beibei Chen and Caiyun Nie and Weifeng Xu and Shuiping Tu and Hongle Li and Xiaobing Chen},
  title = {{Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model}},
  journal = {Journal of Oncology},
  year = {2022},
  doi = {10.1155/2022/1987705},
}
Figure